Rabbit Recombinant Monoclonal CD22 phospho Y807 antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | IHC | Flow Cyt | WB | |
---|---|---|---|---|
Human | Not recommended | Not recommended | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366).
CD22, SIGLEC2, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, BL-CAM, Siglec-2
Rabbit Recombinant Monoclonal CD22 phospho Y807 antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab247213 is the carrier-free version of Anti-CD22 (phospho Y807) antibody [Y505] ab32040.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.
CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.
CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-CD22 (phospho Y807) antibody [Y505] ab32040, the same antibody clone in a different buffer formulation
Blocking and diluting buffer and concentration: 5% NFDM/TBST
All lanes: Western blot - Anti-CD22 (phospho Y807) antibody [Y505] (Anti-CD22 (phospho Y807) antibody [Y505] ab32040) at 10000 kDa
Lane 1: Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate at 15 µg
Lane 2: Jurkat (Human T cell leukemia T lymphocyte) treated with 10mM Pervanadate for 30 min whole cell lysate at 15 µg
Lane 3: Jurkat (Human T cell leukemia T lymphocyte) treated with 10mM Pervanadate for 30 min whole cell lysate, then the membrane was incubated with alkaline phosphatase for 1 hour at 15 µg
Predicted band size: 95 kDa
Observed band size: 150 kDa
Exposure time: 40s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com